Phase Ib/II open-label, randomised evaluation of second-line atezolizumab (atezo) plus linagliptin (lina) vs ramucirumab (ram) plus paclitaxel (pac) in MORPHEUS-gastric cancer

被引：0

作者：

Lee, J. ^{[1
]}

Ajani, J. A. ^{[2
]}

Chung, H. C. ^{[3
]}

Kang, Y-K. ^{[4
]}

Iqbal, S. ^{[5
]}

Allen, S. ^{[6
]}

Al-Sakaff, N. ^{[7
]}

Decalf, J. ^{[8
]}

Li, S. ^{[9
]}

Pintoffl, J. ^{[7
]}

Sayyed, P. ^{[7
]}

Bang, Y-J. ^{[10
]}

机构：

[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hem Oncol, Seoul, South Korea

[2] MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA

[3] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Dept Med Oncol, Seoul, South Korea

[4] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea

[5] USC Norris Comprehens Canc Ctr, Dept Oncol, Los Angeles, CA USA

[6] Genentech Inc, Oncol Biomarker Dev, South San Francisco, CA USA

[7] F Hoffmann La Roche Ltd, Prod Dev Oncol, Basel, Switzerland

[8] Genentech Inc, Dept Canc Immunol, South San Francisco, CA USA

[9] Biostat Roche China Holding Ltd, Shanghai, Peoples R China

[10] Seoul Natl Univ, Internal Med, Coll Med, Seoul, South Korea

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.1491

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1382P

引用

页码：S1047 / S1047

页数：1

共 50 条

[41] Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial
Kawazoe, Akihito
Fukuoka, Shota
Nakamura, Yoshiaki
Kuboki, Yasutoshi
Wakabayashi, Masashi
Nomura, Shogo
Mikamoto, Yuichi
Shima, Hikari
Fujishiro, Noriko
Higuchi, Tsukiko
Sato, Akihiro
Kuwata, Takeshi
Shitara, Kohei
LANCET ONCOLOGY, 2020, 21 (08): : 1057 - 1065
[42] A phase II, open-label, multicenter, prospective study of paclitaxel plus capecitabine with subsequent capecitabine maintenance therapy as first-line treatment for metastatic or recurrent gastric cancer
Shen, L.
Gong, J.
Zhang, X.
Hu, B.
Zhang, F.
Zhang, J.
Xu, N.
Fan, Q.
Bai, Y.
Jiao, S.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
[43] Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial
Baize, Nathalie
Monnet, Isabelle
Greillier, Laurent
Geier, Margaux
Lena, Herve
Janicot, Henri
Vergnenegre, Alain
Crequit, Jacky
Lamy, Regine
Auliac, Jean-Bernard
Letreut, Jacques
Le Caer, Herve
Gervais, Radj
Dansin, Eric
Madroszyk, Anne
Renault, Patrick-Aldo
Le Garff, Gwenaelle
Falchero, Lionel
Berard, Henri
Schott, Roland
Saulnier, Patrick
Chouaid, Christos
LANCET ONCOLOGY, 2020, 21 (09): : 1224 - 1233
[44] Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial
Ebert, Matthias P.
Meindl-Beinker, Nadja M.
Gutting, Tobias
Maenz, Martin
Betge, Johannes
Schulte, Nadine
Zhan, Tianzuo
Weidner, Philip
Burgermeister, Elke
Hofheinz, Ralf
Vogel, Arndt
Angermeier, Stefan
Bolling, Claus
de Wit, Maike
Jakobs, Ralf
Karthaus, Meinolf
Stocker, Gertraud
Thuss-Patience, Peter
Leidig, Tobias
Gaiser, Timo
Kather, Jakob N.
Haertel, Nicolai
LANCET HEALTHY LONGEVITY, 2022, 3 (06): : E417 - E427
[45] Paclitaxel oral solution versus paclitaxel injection as a second-line therapy in advanced gastric cancer: A randomized, open-label, non-inferiority phase 3 trial.
Li, Jin
Huang, Mingzhu
Deng, Ting
Bai, Yuxian
Liu, Tianshu
Pan, Yueyin
Yu, Junyan
Pan, Hongming
Xu, Huiting
Wang, Jufeng
Ye, Feng
Wang, Junye
Wu, Jinsheng
Cang, Shundong
Chen, Kehe
Zhang, Jun
Zhang, Jingdong
Ling, Yang
Liu, Yin
Qin, Shukui
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
[46] Gemcitabine plus Nab-paclitaxel as a second-line treatment for patients with advanced pancreatic cancer after FOLFIRINOX failure: a multicenter, single-arm, open-label, phase 2 trial
Choi, Jin Ho
Lee, Hee Seung
Huh, Gunn
Lee, Sang Hyub
Paik, Woo Hyun
Ryu, Ji Kon
Kim, Yong-Tae
Bang, Seungmin
Lee, Eaum Seok
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 122 - 122
[47] Surufatinib plus doublet (FOLFOX/FOLFIRI) or triplet (FOLFOXIRI) chemotherapy as second-line therapy in metastatic colorectal cancer (mCRC): Updated results of a randomized, open-label, phase II trial
Su, L.
Lin, P.
Huang, F.
Ye, Z.
Li, H.
Zhuo, C.
Wei, S.
Yu, S.
Li, J.
Zheng, S.
Hong, Y.
Zheng, L.
Zhao, S.
Lin, R.
ANNALS OF ONCOLOGY, 2024, 35 : S20 - S20
[48] Toripalimab combined with nab-paclitaxel/docetaxel as second-line treatment in patients with advanced gastric cancer: Preliminary results from a single-arm, open-label phase II trial
Zhang, T.
Yu, D.
Wang, J.
Liu, J.
Ma, H.
Lin, Z.
Jin, M.
Zhang, J.
Zhao, L.
Liu, H.
Hu, J.
Zhang, Q.
ANNALS OF ONCOLOGY, 2021, 32 : S1057 - S1058
[49] PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer
Evrard, Camille
Louvet, Christophe
Hajbi, Farid E. L.
Fiore, Frederic D., I
Malicot, Karine L. E.
Aparicio, Thomas
Bouche, Olivier
Laurent-Puig, Pierre
Bibeau, Frederic
Lecomte, Thierry
Lievre, Astrid
Guimbaud, Rosine
Kim, Stefano
Zaanan, Aziz
Sokol, Harry
Chibaudel, Benoist
Desrame, Jerome
Pierre, Sabrina
Gonzalez, Daniel
Lepage, Come
Tougeron, David
DIGESTIVE AND LIVER DISEASE, 2021, 53 (04) : 420 - 426
[50] Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multi-center, phase II study
Cheng, Yu
Teng, Zan
Zhang, Yanqiao
Jin, Bo
Zheng, Zhendong
Man, Li
Wang, Zhenghua
Teng, Yuee
Yu, Ping
Shi, Jing
Luo, Ying
Wang, Ying
Zhang, Jingdong
Zhang, Huijuan
Liu, Jiwei
Chen, Hao
Xiao, Jiawen
Zhao, Lei
Zhang, Lingyun
Jiang, Yu
Chen, Ying
Zhang, Jian
Wang, Chang
Liu, Sa
Qu, Jinglei
Qu, Xiujuan
Liu, Yunpeng
BMC CANCER, 2024, 24 (01)

← 1 2 3 4 5 →